Multiple sclerosis risk sharing scheme: A costly failure

BMJ (Online)

Volumn 340, Issue 7759, 2010, Pages 1282-1284

  Raftery, James ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; DRUG COST; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; MULTIPLE SCLEROSIS; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; RISK SHARING, FINANCIAL; STATE MEDICINE;

EID: 77953704571     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1672     Document Type: Article

References (18)

1. NICE. Multiple sclerosis - beta interferon and glatiramer acetate. Technology appraisal 32. 2002. www.nice.org.uk/Guidance/TA32.
2. Health Service Circular HSC 2002/004. Cost effective provision of disease modifying therapies for people with multiple sclerosis. www.dh.gov.uk/dr- consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-4012214.pdf.
3. Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677.[Abstract/Free Full Text]
4. Department of Health. Pharmaceutical Pricing Regulation Scheme 2009. www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/ Pharmaceuticalpriceregulationscheme/2009PPRS/DH-090499.
5. Warlow C. Not such a bright idea: the UK risk sharing scheme for beta interferon and glatiramer acetate in multiple sclerosis. Pract Neurol 2003;3:194-5.[Abstract/Free Full Text]
6. McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, et al. Two year results from the United Kingdom multiple sclerosis risk sharing scheme: a commentary. BMJ 2009;340:c1786.
7. Multiple Sclerosis Society. The risk sharing scheme for disease modifying therapies in multiple sclerosis. 2007. www.bayerscheringpharma.co.uk/html/news- documents/Risk-Sharing-Scheme-for-MS.pdf.
8. Keen A. Multiple sclerosis: drugs. House of Commons Hansard written answers 28 Oct, 2008. www.publications.parliament.uk/pa/cm200708/cmhansrd/ cm081028/text/81028w0029.htm.
9. Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study: early results and lessons for the future. BMC Neurology 2009;9:1. [CrossRef][Medline]
10. Keen A. Parliamentary written question and answers, 24 November 2008. www.theyworkforyou.com/wrans/?id=2008-11-24f.237791.h.
11. House of Commons Health Committee Top up fees. Para 118. 2009. http://www.publications.parliament.uk/pa/cm200809/cmselect/cmhealth/194i/194i02. htm
12. McCabe C, Stafinski T, Edlin R, Menon D, Banff AED summit. Access with evidence development schemes. A framework for description and evaluation. Pharmacoeconomics 2010;28:143-52. [CrossRef][Web of Science][Medline]
13. Menon D, McCabe C, Stafinski T, Edlin R. Principles of design of access with evidence development approaches. A consensus statement from the Banff summit. Pharmacoeconomics 2010;28:109-11. [CrossRef][Web of Science][Medline]
14. Sudlow C, Counsell CE. Problems with the UK governments's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003;326:388-92.[Free Full Text]
15. NICE. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. Technology appraisal 27. 2007. http://guidance.nice.org.uk/TA127.
16. Multiple Sclerosis Society. Risky Department of Health scheme failing people with MS. Press release 2 Dec, 2009. www.mssociety.org.uk/news-events/ news/press-releases/rss-failed.html.
17. Keogh A, McNeil K, Williams TJ, Gabbay E, Proudman S, Weintraub RG, et al. The Bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern Med J 2009 [Epub ahead of print].
18. Owen AJ, Spinks J Meehan A, Robb T, Hardy M, Kwasha D, et al. A new model to evaluate the long term cost effectiveness of orphan and highly specialised drugs following listing on the Australian pharmaceutical benefits scheme: the Bosentan patient registry. J Med Econ 2008;11:235-43.[Medline]